Treatment with tofacitinib, an oral Janus kinase inhibitor, has shown improvements in nail psoriasis at week 16 compared with placebo, according to a new study. These improvements have been maintained over 52 weeks.
The mainstay of atopic dermatitis (AD) treatment has been topical agents such as emollients and corticosteroids. However, newer agents such as topical calcineurin inhibitors may be just as effective as and safer than topical corticosteroids, says an expert.
Squamous cell carcinoma arising within seborrheic keratosis (SCC-SK) appears to be more frequent in elderly men with a history of immunosuppression associated with organ transplants, according to a recent study.
Patients with moderate-to-severe atopic dermatitis may benefit from a 52-week treatment course of dupilumab in addition to standard-of-care treatment, according to the results of the phase III LIBERTY AD CHRONOS* trial.
Bilastine is a novel second-generation antihistamine that optimizes the treatment of chronic urticaria and allergic rhinitis by effectively balancing its symptom-relieving effects with a unique safety profile. At the recent European Academy of Allergy and Clinical Immunology (EAACI) Congress held in Vienna, Austria, Professor Marcus Maurer of the Charité-Universitätsmedizen, Berlin, Germany, and Associate Professor Marysia Recto of the Asian Hospital and Medical Centre, Muntinlupa City, Philippines, outlined bilastine’s effects on patients with chronic urticaria and allergic rhinitis, while Professor Piotr Kuna from the Medical University of Lodz, Poland, described its unique pharmacokinetics. Their presentations highlighted the unique traits that have ensured that bilastine is the only second-generation antihistamine to meet most of the desired features of an ideal drug described by international guidelines such as ARIA (Allergic Rhinitis and its Impact of Asthma), most notably its rapid onset of action and long-lasting effect, which are achieved without sedation.